Canton Strategic Holdings (CNTN) Non Operating Income (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Non Operating Income of -$14.7 million for Q1 2026, down 296074.34% on a YoY basis from N/an in Q1 2025, and up 33.17% quarter-over-quarter from -$22.0 million in Q4 2025.
Canton Strategic Holdings (CNTN) Non Operating Income (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Non Operating Income for 6 years, with the latest figure at -$14.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 296074.34% year-over-year to -$14.7 million; the trailing twelve-month figure through Mar 2026 stood at -$36.7 million (down 24565.74% YoY), and the FY2025 full-year result was -$22.0 million, down 9412.05% from the prior year.
- Non Operating Income for Q1 2026 stood at -$14.7 million, up from -$22.0 million in the prior quarter.
- The five-year high for Non Operating Income was $91194.0 in Q1 2024, with the low at -$22.0 million in Q4 2025.
- Historically, Non Operating Income has averaged -$2.7 million across 5 years, with a median of $25532.5 in 2023.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 249.27% — and 2026, when it plunged 296074.34%.
- Canton Strategic Holdings' Non Operating Income stood at -$1.6 million in 2022, then jumped by 103.61% to $57379.0 in 2023, then sank by 53.09% to $26914.0 in 2024, then tumbled by 81804.72% to -$22.0 million in 2025, then jumped by 33.17% to -$14.7 million in 2026.
- The last three Non Operating Income figures came in at -$14.7 million (Q1 2026), -$22.0 million (Q4 2025), and -$8260.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | -14.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.70 Mn |
| Dec 31, 2025 | -21.99 Mn |
| Sep 30, 2025 | -8,260.00 |
| Jun 30, 2025 | -3,993.00 |
| Mar 31, 2025 | 4,965.00 |
| Dec 31, 2024 | 26,914.00 |
| Sep 30, 2024 | 69,719.00 |
| Jun 30, 2024 | 48,397.00 |
| Mar 31, 2024 | 91,194.00 |
| Dec 31, 2023 | 57,379.00 |
| Sep 30, 2023 | 24,955.00 |
| Jun 30, 2023 | 27,682.00 |
| Mar 31, 2023 | 26,110.00 |
| Mar 31, 2022 | -1.59 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | -312,323.00 |
| Jun 30, 2021 | -458,371.00 |
| Mar 31, 2021 | -782,463.00 |